https://www.PR.com/ Latest news releases from PR.com for La Merie Business Intelligence. Fri, 09 Oct 2026 13:23:26 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/40543 Fri, 01 Jun 2007 03:00:00 -0400 The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio [PR.com] https://www.pr.com/press-release/40543 La Merie Business Intelligence https://www.pr.com/press-release/31488 Mon, 05 Mar 2007 11:44:00 -0500 Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. [PR.com] https://www.pr.com/press-release/31488 La Merie Business Intelligence https://www.pr.com/press-release/31087 Tue, 27 Feb 2007 03:00:00 -0500 Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still No. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4%), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25%). [PR.com] https://www.pr.com/press-release/31087 La Merie Business Intelligence https://www.pr.com/press-release/29069 Tue, 06 Feb 2007 03:00:00 -0500 The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide posted 2006 sales of US$ 430.2 mln in the first full market year and gained FDA approval for expanded combination use. A once-daily [PR.com] https://www.pr.com/press-release/29069 La Merie Business Intelligence https://www.pr.com/press-release/28898 Mon, 05 Feb 2007 11:45:00 -0500 A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. [PR.com] https://www.pr.com/press-release/28898 La Merie Business Intelligence https://www.pr.com/press-release/26813 Fri, 12 Jan 2007 03:00:00 -0500 A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. [PR.com] https://www.pr.com/press-release/26813 La Merie Business Intelligence https://www.pr.com/press-release/18117 Wed, 20 Sep 2006 03:00:00 -0400 The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection. [PR.com] https://www.pr.com/press-release/18117 La Merie Business Intelligence https://www.pr.com/press-release/17253 Fri, 08 Sep 2006 03:00:00 -0400 Anti-TNF agents set the new gold standard of psoriasis treatment which could be outperformed by smarter next generation biologics and small molecules in safety and convenience. [PR.com] https://www.pr.com/press-release/17253 La Merie Business Intelligence https://www.pr.com/press-release/15895 Thu, 17 Aug 2006 03:00:00 -0400 The versatility of the vascular endothelial growth factor (VEGF) signalling pathway as a validated target and its excellent tractability explain a crowded field of drugs of all classes. [PR.com] https://www.pr.com/press-release/15895 La Merie Business Intelligence https://www.pr.com/press-release/14993 Wed, 02 Aug 2006 03:00:00 -0400 The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds including improved TNF-antagonists and molecules originating from new technologies. [PR.com] https://www.pr.com/press-release/14993 La Merie Business Intelligence https://www.pr.com/press-release/12521 Tue, 20 Jun 2006 03:00:00 -0400 The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions. [PR.com] https://www.pr.com/press-release/12521 La Merie Business Intelligence https://www.pr.com/press-release/11694 Sat, 03 Jun 2006 03:00:00 -0400 The Business Intelligence firm La Merie S.L. reported today changes in the field of erythropoiesis stimulating agents (ESA) observed in a follow-up analysis. The first launch of a new ESA in Europe is expected to be Shire’s epoetin omega in the first half of 2007 to be followed by Roche’s next generation pegylated erythropoietin (EPO) product CERA in the second half of 2007. As the filing of the first [PR.com] https://www.pr.com/press-release/11694 La Merie Business Intelligence https://www.pr.com/press-release/11445 Wed, 31 May 2006 03:00:00 -0400 The Localized delivery of phosphodiesterase-4 (PDE-4) inhibitors appears to be short term solution to overcome the dose-limiting side effects of severe nausea and emesis occurring after oral administration. In the long-term, subtype-selective PDE-4 inhibitors and combination regimens may help to improve the therapeutic index. [PR.com] https://www.pr.com/press-release/11445 La Merie Business Intelligence https://www.pr.com/press-release/10923 Fri, 19 May 2006 08:56:10 -0400 The interferon alpha market is smaller than the interferon beta market, but is characterized by far more products and R&D projects. Conversion of the interferon alpha market to pegylated products explains why new R&D is focused on interferon alpha variants or other subtypes with improved pharmacodynamic and safety properties. [PR.com] https://www.pr.com/press-release/10923 La Merie Business Intelligence https://www.pr.com/press-release/10453 Wed, 10 May 2006 03:00:00 -0400 The Business Intelligence firm La Merie S.L. reported today that the RNAi therapeutic pipeline is rapidly filling and advancing towards clinical development. Four RNAi therapeutic projects are in early clinical development. At least 32 RNAi projects are in preclinical development in a variety of therapeutic areas. Viral diseases and cancer are the preferred indications. A total of 14 RNAi projects are approaching IND [PR.com] https://www.pr.com/press-release/10453 La Merie Business Intelligence https://www.pr.com/press-release/7579 Tue, 07 Mar 2006 02:35:00 -0500 At least six fully human or humanized antibodies against insulin-like growth factor-1 receptor (IGF-1R) are in early clinical development or close to phase I. [PR.com] https://www.pr.com/press-release/7579 La Merie Business Intelligence https://www.pr.com/press-release/7051 Wed, 22 Feb 2006 09:00:00 -0500 Tremendous impetus to discovery of novel CB1 antagonists by first-in-class CB1 receptor antagonist rimonabant under review by FDA and EMEA [PR.com] https://www.pr.com/press-release/7051 La Merie Business Intelligence https://www.pr.com/press-release/6758 Wed, 15 Feb 2006 03:49:00 -0500 The Top 20 blockbuster recombinant proteins and antibodies achieved record sales of US$ 37.7 bln in the year 2005 while combined sales of the 12 Top selling classes of recombinant proteins and antibodies reached the US$ 50 bln threshold. [PR.com] https://www.pr.com/press-release/6758 La Merie Business Intelligence https://www.pr.com/press-release/6417 Tue, 07 Feb 2006 09:00:00 -0500 Twice-daily injection is the benchmark set by exenatide, the first GLP-1 analog launched in the US by Lilly in June 2005 and half-year sales of US$ 74.6 mln, which now faces competition by GLP-1 analog treatment modalities with less frequent dosing. [PR.com] https://www.pr.com/press-release/6417 La Merie Business Intelligence https://www.pr.com/press-release/6134 Tue, 31 Jan 2006 09:00:00 -0500 The complexity of glucose metabolism and the number of cellular processes affected by diabetes provides ample space for new drug targets and for first-in-class molecules. Some of them have reached or are close to early clinical development in type 2 diabetes. [PR.com] https://www.pr.com/press-release/6134 La Merie Business Intelligence https://www.pr.com/press-release/5874 Tue, 24 Jan 2006 01:00:00 -0500 A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 diabetes. SGLT inhibitors do not intervene with glucose metabolism, thus being complementary to mainstream approaches to glucose regulation, i.e. PPAR agonists, DPP-IV antagonists and GLP-1 analogues. [PR.com] https://www.pr.com/press-release/5874 La Merie Business Intelligence https://www.pr.com/press-release/4390 Mon, 28 Nov 2005 12:03:26 -0500 The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %). [PR.com] https://www.pr.com/press-release/4390 La Merie Business Intelligence https://www.pr.com/press-release/4097 Mon, 14 Nov 2005 10:19:50 -0500 Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta). [PR.com] https://www.pr.com/press-release/4097 La Merie Business Intelligence